Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism

Haematologica

Volumn 101, Issue 9, 2016, Pages 1046-1053

  Gran, Olga V ^a   Smith, Erin N ^b,c,d   Brækkan, Sigrid K ^a,e   Jensvoll, Hilde ^a,e   Solomon, Terry ^d   Hindberg, Kristian ^a   Wilsgaard, Tom ^a   Rosendaal, Frits R ^a,f   Frazer, Kelly A ^a,b   Hansen, John Bjarne ^a,e  

^a UNIVERSITY OF TROMSØ   (Norway)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 5;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEOPLASM; PANCREAS CANCER; PHYSICAL ACTIVITY; RISK FACTOR; SMOKING; VENOUS THROMBOEMBOLISM; ALLELE; COMPLICATION; GENETIC VARIATION; GENETICS; HEALTH SURVEY; INCIDENCE; KAPLAN MEIER METHOD; MORTALITY; PROPORTIONAL HAZARDS MODEL; RISK; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; FACTOR V; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; RISK; VENOUS THROMBOEMBOLISM;

EID: 84986211331     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.147405     Document Type: Article

References (56)

1. Heit JA. Venous thromboembolism: Disease burden, outcomes and risk factors. J Thromb Haemost. 2005;3(8):1611-1617.
2. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: A population-based study. J Thromb Haemost. 2007;5(4):692-699.
3. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: The longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117(1):19-25.
4. Bouillaud S. De l’obliteration des veines et de son influence sur la formation des hydropisies partielles: Considerations sur l’hydropisie passive et generale. Arch Gen Med. 1823;1:188-204.
5. Trousseau A. CJt. Lectures on clinical medicine:Delivered at the Hotel-Dieu, Paris. The New Syndenham Society 1872.
6. Agnelli G, Verso M. Thrombosis and cancer:clinical relevance of a dangerous liaison. Haematologica. 2005;90(2):154-156.
7. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med. 2000;160(6):809-815.
8. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancerassociated venous thrombosis. Blood. 2013;122(10):1712-1723.
9. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846-1850.
10. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-634.
11. Monreal M, Trujillo-Santos J. Lessons from VTE registries: The RIETE experience. Best Pract Res Clin Haematol. 2009;22(1):25-33.
12. Larsen TB, Sorensen HT, Skytthe A, Johnsen SP, Vaupel JW, Christensen K. Major genetic susceptibility for venous thromboembolism in men: A study of Danish twins. Epidemiology. 2003;14(3):328-332.
13. Souto JC, Almasy L, Borrell M, et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors:the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am J Hum Genet. 2000;67(6):1452-1459.
14. Morange PE, Tregouet DA. Current knowledge on the genetics of incident venous thrombosis. J Thromb Haemost. 2013;11 (Suppl 1):111-121.
15. Heit JA, Cunningham JM, Petterson TM, Armasu SM, Rider DN, de Andrade M. Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism. J Thromb Haemost. 2011;9(6):1133-1142.
16. Mann KG, Kalafatis M. Factor V: A combination of Dr Jekyll and Mr Hyde. Blood. 2003;101(1):20-30.
17. Nicolaes GA, Dahlback B. Factor V and thrombotic disease: Description of a Janusfaced protein. Arterioscler Thromb Vasc Biol. 2002;22(4):530-538.
18. Vos HL. Inherited defects of coagulation factor V: The thrombotic side. J Thromb Haemost. 2006;4(1):35-40.
19. Kostka H, Siegert G, Schwarz T, et al. Frequency of polymorphisms in the Bdomain of factor V gene in APC-resistant patients. Thromb Res. 2000;99(6):539-547.
20. Severinsen MT, Overvad K, Johnsen SP, et al. Genetic susceptibility, smoking, obesity and risk of venous thromboembolism. Br J Haematol. 2010;149(2):273-279.
21. Kujovich JL. Factor V Leiden thrombophilia. Genet Med. 2011;13(1):1-16.
22. Sode BF, Allin KH, Dahl M, Gyntelberg F, Nordestgaard BG. Risk of venous thromboembolism and myocardial infarction associated with factor V Leiden and prothrombin mutations and blood type. CMAJ. 2013;185(5):E229-237.
23. Rees DC. The population genetics of factor V Leiden (Arg506Gln). Br J Haematol. 1996;95(4):579-586.
24. Pihusch R, Danzl G, Scholz M, et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer. 2002;94(12):3120-3126.
25. Blom JW, Doggen CM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715-722.
26. Kennedy M, Andreescu ACM, Greenblatt MS, et al. Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients. Br J Haematol. 2005;128(3):386-388.
27. Eroglu A, Ulu A, Cam R, Kurtman C, Akar N. Prevalence of factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients. J Thromb Thrombolysis. 2007;23(1):31-34.
28. Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njølstad I. Cohort profile: The Tromsø study. Int J Epidemiol. 2011;41(4):961-967.
29. White RH, Chew HK, Zhou H, et al. INcidence of venous thromboembolism in the year before the diagnosis of cancer in 528 693 adults. Arch Intern Med. 2005;165(15):1782-1787.
30. Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer. 2013;49(6):1404-1413.
31. Blix K, Severinsen M, Braekkan S, et al. Cancer-related venous thromboembolism in the general population: Results from the Scandinavian Thrombosis and Cancer (STAC) study. J Thromb Haemost. 2015; 13(Suppl 2):549.
32. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
33. Morange PE, Tregouet DA. Lessons from genome-wide association studies in venous thrombosis. J Thromb Haemost. 2011;9 (Suppl 1):258-264.
34. Germain M, Chasman Daniel I, de Haan H, et al. Meta-analysis of 65,734 Individuals Identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism. Am J Hum Genet. 2015;96(4):532-542.
35. Mozsik G, Rumi G, Domotor A, et al. Involvement of serum retinoids and Leiden mutation in patients with esophageal, gastric, liver, pancreatic, and colorectal cancers in Hungary. World J Gastroenterol. 2005;11(48):7646-7650.
36. Bezemer ID, Bare LA, Doggen CJ, et al. Gene variants associated with deep vein thrombosis. JAMA. 2008;299(11):1306-1314.
37. Smith NL, Hindorff LA, Heckbert SR, et al. Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA. 2007;297(5):489-498.
38. Dahm AE, Tiscia G, Holmgren A, et al. Genetic variations in the annexin A5 gene and the risk of pregnancy-related venous thrombosis. J Thromb Haemost. 2015;13 (3):409-413.
39. Corral J, Roldán V, Vicente V. Deep venous thrombosis or pulmonary embolism and factor V Leiden: Enigma or paradox. Haematologica. 2010;95(6):863-866.
40. Ravin AJ, Edwards RP, Akrohn M, Kelley JR, Christopherson WA, Roberts JM. The factor V Leiden mutation and the risk of venous thromboembolism in gynecologic oncology patients. Obstet Gynecol. 2002;100(6):1285-1289.
41. Ramacciotti E, Wolosker N, Puech-Leao P, et al. Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res. 2003;109(4):171-174.
42. Otterson GA, Monahan BP, Harold N, Steinberg SM, Frame JN, Kaye FJ. Clinical significance of the FV:Q506 mutation in unselected oncology patients. Am J Med. 1996;101(4):406-412.
43. Pabinger I, Ay C, Dunkler D, et al. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS). J Thromb Haemost. 2014;13(1):17-22.
44. Rothman KJ, Greenland S, Walker AM. Concepts of Interaction. Am J Epidemiol. 1980;112(4):467-470.
45. Knol MJ, van der Tweel I, Grobbee DE, Numans ME, Geerlings MI. Estimating interaction on an additive scale between continuous determinants in a logistic regression model. Int J Epidemiol. 2007;36(5): 1111-1118.
46. Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med. 2001;110 (2):91-96.
47. Green D, Maliekel K, Sushko E, Akhtar R, Soff GA. Activated-protein-C resistance in cancer patients. Haemostasis. 1997;27(3):112-118.
48. De Lucia D, De Vita F, Orditura M, et al. Hypercoagulable state in patients with advanced gastrointestinal cancer: Evidence for an acquired resistance to activated protein C. Tumori. 1997;83(6):948-952.
49. Vandenbroucke JP, Koster T, Rosendaal FR, Briët E, Reitsma PH, Bertina RM. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344(8935):1453-1457.
50. Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995;173(1):210-213.
51. Rosendaal FR. Venous thrombosis: A multicausal disease. Lancet. 1999;353(9159):1167-1173.
52. Di Nisio M, Porreca E, Otten HM, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2014;(8):CD008500.
53. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients:Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):e195S-226S.
54. Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer:American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189-2204.
55. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907.
56. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377-5382.